Outcome of elderly patients with classical Hodgkin’s lymphoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73603529" target="_blank" >RIV/61989592:15110/20:73603529 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/20:10409558 RIV/00216208:11120/20:43919707 RIV/00216208:11150/20:10409558 RIV/00179906:_____/20:10409558 RIV/00064165:_____/20:10409558

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0145212620300163" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0145212620300163</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.leukres.2020.106311" target="_blank" >10.1016/j.leukres.2020.106311</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcome of elderly patients with classical Hodgkin’s lymphoma

Popis výsledku v původním jazyce

Introduction The optimal management of elderly patients (pts) with Hodgkin&apos;s lymphoma is not yet defined. The aims of the present study were: 1) to evaluate clinical and laboratory characteristics of elderly pts; 2) to indentify risk factors for unfavorable outcome. Patients and methods The outcome of 182 pts ≥ 60 years (y) was retrospectively analyzed (median age, 67y). Mixed cellularity histology was diagnosed in 49.5 %, advanced stage of disease was in 68.7 % pts, CIRS &gt; 3 in 35.7 %, ECOG PS ≥ 2 in 22.9 % (60-69y) of pts. Chemotherapy (CMT) alone was used in 69.2 % and combination of CMT and radiotherapy in 26.9 % of pts. Anthracycline-based CMT received 83.5 % of pts. The median follow-up was 4.5y. Results The overall response/complete remission rate was 85.6/70.7 %. The median progression free survival (PFS) and overall survival (OS) were 10y and 11.3y, respectively. Estimated 5-y PFS and 5-y OS were 65.7 % (in contrast to 98.2 % in pts &lt; 60y; p &lt; 0.001) and 70.5 % (99.4 % in pts &lt; 60y; p &lt; 0.001). Overall 70 (38.5 %) elderly pts died. The independent risk factors for a shorter OS included CIRS &gt; 3, lymphopenia &lt; 8 % and anthracycline-free CMT, for a shorter PFS anthracycline-free CMT and lymphopenia &lt; 8 %. Conclusion CIRS &gt; 3, lymphopenia &lt; 8 % and anthracycline-free chemotherapy appear to be significant for unfavorable outcome.

Název v anglickém jazyce

Outcome of elderly patients with classical Hodgkin’s lymphoma

Popis výsledku anglicky

Introduction The optimal management of elderly patients (pts) with Hodgkin&apos;s lymphoma is not yet defined. The aims of the present study were: 1) to evaluate clinical and laboratory characteristics of elderly pts; 2) to indentify risk factors for unfavorable outcome. Patients and methods The outcome of 182 pts ≥ 60 years (y) was retrospectively analyzed (median age, 67y). Mixed cellularity histology was diagnosed in 49.5 %, advanced stage of disease was in 68.7 % pts, CIRS &gt; 3 in 35.7 %, ECOG PS ≥ 2 in 22.9 % (60-69y) of pts. Chemotherapy (CMT) alone was used in 69.2 % and combination of CMT and radiotherapy in 26.9 % of pts. Anthracycline-based CMT received 83.5 % of pts. The median follow-up was 4.5y. Results The overall response/complete remission rate was 85.6/70.7 %. The median progression free survival (PFS) and overall survival (OS) were 10y and 11.3y, respectively. Estimated 5-y PFS and 5-y OS were 65.7 % (in contrast to 98.2 % in pts &lt; 60y; p &lt; 0.001) and 70.5 % (99.4 % in pts &lt; 60y; p &lt; 0.001). Overall 70 (38.5 %) elderly pts died. The independent risk factors for a shorter OS included CIRS &gt; 3, lymphopenia &lt; 8 % and anthracycline-free CMT, for a shorter PFS anthracycline-free CMT and lymphopenia &lt; 8 %. Conclusion CIRS &gt; 3, lymphopenia &lt; 8 % and anthracycline-free chemotherapy appear to be significant for unfavorable outcome.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV16-29857A" target="_blank" >NV16-29857A: Narušení kognice, strukturální a funkčně morfologické změny mozku při léčbě Hodgkinova lymfomu: translační studie.</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

LEUKEMIA RESEARCH

ISSN

0145-2126

e-ISSN

—

Svazek periodika

90

Číslo periodika v rámci svazku

March 2020

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

"'106311(1)'"-"'106311(7)'"

Kód UT WoS článku

000516786500005

EID výsledku v databázi Scopus

2-s2.0-85079048652